10 Best Mid Cap Biotech Stocks to Buy

2. Revolution Medicines, Inc. (NASDAQ:RVMD)

Market Cap: $7.15 billion

Number of Hedge Fund Holders: 60

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.

The company ended fiscal Q4 2024 with $2.3 billion in cash and investments. This includes $823 million raised from an equity offering, which is anticipated to fund operations into the latter half of 2027. Analysts are bullish on the stock as this financial strength supports Revolution Medicines, Inc. (NASDAQ:RVMD) in its ongoing and future initiatives. Its median price target of $38.45 implies an upside of 85.96% from current levels.

Revolution Medicines, Inc. (NASDAQ:RVMD) has also entered into strategic collaborations to bolster its treatment strategies. These include a bispecific antibodies development collaboration with Aethon Therapeutics and a PRMT5 inhibitor partnership with Tango. These collaborations are expected to expand the company’s therapeutic offerings and expedite development timelines. On March 3, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines, Inc. (NASDAQ:RVMD) to $73 from $72 and kept a Buy rating on the company. It takes the second spot on our list of the 10 best mid cap biotech stocks to invest in.